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Introduction
Recent years have seen the advent of nonmammalian models
(such as Drosophila, C. elegans, zebrafish, and yeast) for drug
discovery and development. This has been driven in part by the
completion of genome sequences and new methodologies that
facilitate somatic cell genetics, such as gene knockout and RNA
interference (for reviews, see Amatruda et al., 2002; Dean et al.,
2001; Hudson et al., 2002; Kumar and Snyder, 2001; Paddison
and Hannon, 2002). Such advances enable the manipulation of
a single gene product in the context of isogenic cell systems
and multicellular organisms in order to investigate drug action.
The myriad genetic tools available to study wide-ranging condi-
tional and null mutant phenotypes in haploid cells, coupled with
the high degree of conservation of basic cell cycle machinery,
render the yeast Saccharomyces cerevisiae particularly invalu-
able for studies of cellular pharmacology and cancer therapeu-
tics (Forsburg, 2001; Kumar and Snyder, 2001; Ma, 2001; Reid
et al., 1998; Sherman, 2002).This genetically tractable microor-
ganism is amenable to the manipulations necessary to identify
the cellular target of a chemotherapeutic agent or to decipher
the pathways and processes that modulate cell sensitivity to a
given agent. Drug-induced synthetic lethality in different yeast
mutants can also be exploited to define specific genetic defects
in cancer cells that potentiate therapy-induced cytotoxicity.
Ultimately, a more thorough understanding of drug mechanism
provides a conceptual framework for the clinical development of
novel therapeutics and the identification of new targets for drug
development.
Yeast as a model system
The haploid genome of the budding yeast S. cerevisiae is of rel-
atively low complexity (1.2 × 107 bp) and is packaged into 16
well-characterized chromosomes (Cherry et al., 1997).This was
the first eukaryotic genome for which the complete sequence
was reported, with ?6,000 open reading frames (ORFs) pre-
dicted to encode proteins of ≥ 100 amino acid residues
(Goffeau et al., 1996). The relative scarcity and limited size of
introns contributes to an average gene size of 1.5 kb. Annotated
information on gene and protein functions is available through
several databases, including the Saccharomyces Genome
Database (SGD), with links to databases such as Gene
Ontology (GO), which provides comparative analyses of gene
product functions from different model organisms, and the
GRID database of genetic and physical interactions (Ball et al.,
2001; Dwight et al., 2002; Issel-Tarver et al., 2002). Curated pro-
tein databases, such as the Yeast Protein Database (YPD), are
also maintained as part of a collection of protein databases
from other fungal and more complex eukaryotic systems that
comprise the BioKnowledge Library (Csank et al., 2002).
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The Saccharomyces Genome Deletion Project consortium
has deleted over 95% of the predicted ORFs in the yeast
genome with a kanMX4 resistance module flanked by unique
20-mer sequences (Giaever et al., 2002; Shoemaker et al.,
1996). This, in essence, barcodes each gene deletion such that
the under- or overrepresentation of a given deletion in pooled
cultures can be assessed under various conditions by
hybridization to high-density oligonucleotide arrays. About 20%
of yeast genes are essential for growth in rich media and, one-
third of yeast genes have been extensively characterized.
Nevertheless, over 30% of yeast ORFs have no known function.
S. cerevisiae is a useful model system with which to study
cellular processes and pathways that have proven intractable in
higher eukaryotes. In part, the utility of this organism lies in its
facile genetics and in highly conserved cell cycle machinery and
metabolic pathways, with clear human orthologs (Forsburg,
2001; Kumar and Snyder, 2001; Sherman, 2002). This microor-
ganism has the added advantage of rapid growth, as dispersed
single haploid or diploid cells, where recessive mutant pheno-
types may be analyzed in mitotically stable haploid strains. Also
characteristic of budding yeast is relatively high rates of homol-
ogous recombination. The predominance of recombination
between homologous sequences allows for the precise inser-
tion of DNA sequences at specific locations within the yeast
genome (Rothstein, 1991). In combination with PCR-based
methods, it is rather trivial to replace a gene with a selectable
marker or a mutant allele (Johnston et al., 2002). Similar
approaches can be used to introduce regulated promoters
upstream of a given ORF or epitope/GFP (green fluorescent
protein) tags within a coding region (Longtine et al., 1998). This
has been facilitated by the availability of a variety of selectable
markers (see Table 1) such as the URA3 gene, which restores
uracil prototrophy (ability to grow on media lacking uracil) to a
strain harboring a nonreverting ura3 mutant allele.
Another aspect of yeast cell biology that facilitates the
analysis of drug action is the availability of DNA vectors that can
be maintained as episomal plasmids or integrated into the
genome via homologous recombination (Table 1) (Christianson
et al., 1992; Funk et al., 2002; Sikorski and Hieter, 1989). In low
copy YCp vectors, the presence of centromeric DNA (such as
CEN6) and an ARS origin of replication ensure the mitotic sta-
bility of DNA molecules that replicate once per cell cycle. In YEp
vectors (20–50 copies/cell), the 2 µm origin is derived from a
naturally occurring plasmid. These shuttle vectors also contain
DNA elements necessary for amplification in bacteria.
If the cellular target of a drug of interest is known, then
genetic screens can be designed to define events upstream or
downstream of drug-target interactions that dictate cell sensitiv-
ity. If the target is unknown or the mechanism of drug action is
Cancer therapeutics in yeast
Mary-Ann Bjornsti
Department of Molecular Pharmacology, St. Jude Childrens Research Hospital, Memphis, Tennessee 38105
Correspondence: mary-ann.bjornsti@stjude.org
The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular 
target of a given agent and investigate mechanisms of drug action.
268 CANCER CELL : OCTOBER 2002
P R I M E R
unclear, these issues can also be approached genetically,
assuming the starting yeast strain is sensitive to the drug (i.e.,
exhibits a 3-log drop in the number of cells forming colonies
upon drug exposure). Drug inhibitory effects may be either cyto-
toxic or cytostatic. If conditions cannot be empirically deter-
mined that restrict cell growth in the presence of a given agent
(such as alterations in media pH or the introduction of mutations
that increase cell permeability), then genetic approaches may
be used to induce a sensitive phenotype, which may be exploit-
ed in subsequent screens to investigate other aspects of drug
action. For example, in the case of camptothecin, the target of
the drug is DNA topoisomerase I. By deleting the chromosomal
copy of TOP1 and overexpressing a plasmid-borne copy of
TOP1 from the galactose-inducible promoter, the cells exhibit
enhanced sensitivity to camptothecin on galactose-containing
media and are resistant to the drug in the presence of dextrose
(Kauh and Bjornsti, 1995; Reid et al., 1997). The increase in
drug sensitivity overcomes the relative insensitivity of wild-type
yeast strains to camptothecin and simplifies the elimination of
trivial plasmid-borne mutations in TOP1.
Genetic screens to investigate drug action
Genomic approaches have been taken to define cellular
responses to drug and radiation-induced DNA lesions. For
example, Giaever et al. (1999) explored alterations in gene
dosage as a means of identifying drug targets by assessing
alterations in the growth of heterozygous deletion strains, where
only one allele of a given gene was deleted. Screening the set of
homozygous diploid strains deleted for nonessential genes,
Resnick and colleagues defined over 100 loci that function to
modulate cell sensitivity to ionizing radiation (Bennett et al.,
2001). A recent comparison of homozygous diploid deletion
strain survival with transcriptional responses induced by distinct
classes of DNA lesions failed to establish a relationship
Figure 1. Classic genetic screens for drug resistance
This figure depicts independent strategies for conferring a drug-resistant
phenotype in wild-type cells that are sensitive to the growth inhibitory
effects of the drug. On the left, mutations that alter gene functions neces-
sary for drug sensitivity are selected following the exposure of wild-type
cells to a mutagen. The dosage suppressor screen on the right depicts the
selection of drug-resistant cells following transformation of wild-type cells
with a YEp-based multicopy yeast genomic DNA library. The increased
expression of plasmid-encoded genes confers drug resistance.
Table 1. Yeast nomenclature and toolsa
Symbol Definition
YFG1 (Your Favorite Gene)b Gene (wild-type allele or dominant 
mutant)
ygf1 Recessive mutant allele
ygf1∆ Deletion mutant
ygf1-1 Specific mutant allele or mutation
Ygf1p Protein product
Marker Selection
URA3 Media lacking uracilc
LEU2 Media lacking leucine
HIS3d Media lacking histidine
TRP1 Media lacking tryptophane
kanMX4 Kanamycin/G418 resistance
GFPf Nonefluoresces green when exposed to
U.V. light
Promoter Characteristics
GAL1 Regulated: glucose-repressed, 
galactose-induced
CUP1 Regulated: copper-inducible
MET15 Regulated: methionine-repressed
ADH Constitutive
GPD Strong constitutive
Vectorg Characteristics
YCp (centromeric plasmid) Centromere (CEN)/origin of replication
low copy number (ARS) ensure mitotic stability
Bacterial AmpR and ori
YEp (episomal plasmid) 2 µm origin of replication from yeast
high copy number 2 µm plasmid
Bacterial AmpR and ori
YIp (integrating plasmid) Bacterial AmpR and ori
a Representative examples are given for each category.
b Yeast genes have three-letter names that are often acronyms of descrip-
tions of specific pathways or biological functions.
c URA3 encodes orotidine-5-phosphate decarboxylase. Negative selec-
tion: ura3 auxotrophs are resistant to 5-FOA (5-fluoro-orotic acid).
d his5+ from the fission yeast, Schizosaccharomyces pombe, will also com-
plement S. cerevisiae his3 auxotrophs.
e TRP1 encodes phosphoribosylanthranilate isomerase. Negative selection:
trp1 auxotrophs are resistant to 5-FAA (5-fluoroanthranilic acid).
f GFP encodes green fluorescent protein. A yeast codon corrected GFP
variant is used.
g The pRS series of centromeric, episomal, and integrating vectors enjoys
wide use, with polylinker sequences flanked by T3/T7 primer sites
(Christianson et al., 1992; Sikorski and Hieter, 1989).
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between increased transcript levels and gene function in medi-
ating cell survival (Birrell et al., 2002). These findings question
the utility of microarray profiling of gene expression in predicting
therapeutic response. Clearly, such approaches provide impor-
tant information regarding drug action; however, they are 
necessarily limited to nonessential genes or pathways that are
sensitive to gene dosage.
This primer will focus on classical genetic screens to inves-
tigate drug action. The advantage of these approaches is the
potential to isolate (1) a broad range of genetic alterations,
including mutations in essential and nonessential genes that
produce a gain-of-function or partial loss-of-function, and (2)
conditional mutations where differences in drug sensitivity are
only observed under certain circumstances, such as high tem-
perature. Another advantage is the ability to incorporate specif-
ic genetic alterations in the parental strain used to set up the
screen.
Yeast sensitivity to drugs
The relative insensitivity of yeast cells to many chemotherapeu-
tic agents limits the utility of this system to study drug action.
Drug resistance may be a consequence of poor permeability,
active drug efflux, the steady state levels of a drug target, or the
absence of specific activities necessary for drug activation
(Kolaczkowska and Goffeau, 1999; Le Crom et al., 2002; Nitiss
and Wang, 1991; Reid et al., 1998; Simon et al., 2000). In cases
where drug permeability or transport is an issue, deletion of
specific components of the PDR drug resistance pathway, such
as the Pdr1p transcription factor or ATP binding cassette trans-
porters (Pdr5p or Snq2p) (Reid et al., 1997; Simon et al., 2000),
or the introduction of mutations that globally affect drug perme-
ability (ise1 or ISE2) (Nitiss and Wang, 1988) can enhance the
cytotoxic activity of a given agent to allow for the selection of
resistant mutants. In cases where the levels of a particular drug
target are at issue, regulated promoters can be introduced to
alter gene expression in order to optimize cell sensitivity (as
described for camptothecin above). While such genetic alter-
ations are impractical to implement on a genomic scale in sets
of deletion strains, they are easily incorporated into a parental
yeast strain used in classical genetic screens.
In cases where a pathway or gene function is completely
lacking in yeast, it may be possible to “humanize” yeast cells by
expressing a human cDNA from a yeast promoter. However, the
utility of this approach depends on the gene/pathway in question.
For example, yeast has not proven useful in the study of nucleo-
side analogs, due to differences in nucleotide salvage and
biosynthetic pathways. However, expression of Herpes simplex
thymidine kinase in yeast that lack this enzyme allows for the cells
to utilize exogenous thymidine or BrdU (Lengronne et al., 2001).
Another example is apoptosis, which convention dictates
occurs exclusively in multicellular organisms. Conceptually, this
was supported by the lack of critical components of the apoptot-
ic apparatus—including caspases and death receptors.
However, the absence of specific processes in a eukaryotic cell
in which other cell cycle, repair, and checkpoint regulatory path-
ways are intact can also be exploited to examine protein 
without the confounding activities of related family members.
For example, the regulated expression of human procaspases,
either alone or in combination, enables a direct assessment of
the hierarchical proteolytic processing and activation of specific
procaspases (Kang et al., 1999). The lethal phenotype induced
by certain caspases could provide the basis for a suppressor
screen or the selection of specific inhibitors. Moreover, recent
studies indicate that a highly regulated cell death program does,
in fact, occur in yeast (Jin and Reed, 2002; Madeo et al., 2002).
Clearly, the design of genetic screens based on the drug-sensi-
tive phenotype of yeast cells expressing a human cDNA must
also consider the relevance of the findings to drug action in
human cells.
Genetic screens: Suppressors of drug sensitivity
In the following discussions of yeast genetic screens, the focus
will be limited to mechanisms of drug action and cellular
processes that determine cellular response.Yeast genetics, cou-
pled with cell biology and biochemistry, have proven invaluable
in defining metabolic and repair pathways, cell cycle machinery,
and checkpoint functions, and in uncovering redundant gene
functions. With regards to drug action, however, the intent is to
Figure 2. Characterization of drug-resistant yfg mutants
This figure depicts the genetic manipulations necessary to determine (1)
whether a mutation in a single YFG gene (for Your Favorite Gene) is suffi-
cient to render cells drug-resistant, or if multiple gene defects are involved,
and (2) if drug resistance is dominant or recessive. The salient features are
backcrossing the mutant strain with wild-type (drug-sensitive) cells of the
opposite mating type and assessing the drug sensitivity of the resultant het-
erozygous diploid cells. The four haploid spore products of a single meiotic
event are encased in an ascus sac. Following enzymatic digestion, individ-
ual spores can be gently microdissected (tetrad dissection) and germinat-
ed on rich media to form independent colonies.
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take advantage of well-defined pathways and/or to place novel
gene functions in the context of known cellular processes.
Two classic genetic screens for drug resistance are dia-
grammed in Figure 1. The scheme on the right is a screen for
high copy suppressors of drug sensitivity. Drug-sensitive cells
are transformed with a genomic DNA library in which random
fragments of yeast DNA are cloned into a YEp-based vector
with a selectable URA3 marker, and resistant colonies are
selected on drug containing media. The underlying principle is
that increased gene copy number of a wild-type gene (20–50
copies per cell) will augment drug resistance (Forsburg, 2001).
For example, if a drug inhibits the activity of an essential rate-
limiting enzyme, then increased enzyme levels would diminish
drug-induced toxicity. Alternatively, an increase in repair path-
ways, a specific drug transporter, or activation of compensatory
pathways would also yield a resistant phenotype. The advan-
tage of this approach is that plasmid-encoded dosage suppres-
sors can be identified by recovering the vector from individual
resistant colonies and querying the database with DNA
sequences obtained from each end of the genomic DNA insert.
Blast searches of yeast genome databases will define the chro-
mosome fragment contained in the plasmid, and provide infor-
mation on the number and identity of putative ORFs.
Subsequent subcloning and rescreening of individual ORFs will
identify the high copy suppressor gene.
A GAL1-promoted cDNA library may also be used to selec-
tively overexpress individual cDNAs on galactose-containing
media (Liu, 2002; Measday and Hieter, 2002).The inclusion of a
single cDNA in each plasmid obviates the need to subclone
individual ORFs and eliminates some of the complications
attendant with promoter regulation. Although both strategies
require DNA libraries of high quality, the greater complexity of
cDNA libraries may necessitate screening of large numbers of
transformants to ensure adequate representation of gene
sequences expressed at low levels.
In a second genetic approach, schematized on the left side
of Figure 1, drug-sensitive haploid cells are subjected to a muta-
gen (such as ethyl methyl sulfonate [EMS] or U.V. light) and
resistant colonies are selected on drug-containing media
(Lawrence, 2002). The premise is that mutation-induced alter-
ations in gene function enhance cellular resistance to drug-
induced effects. For simplicity, the mutation here is in a gene
designation YFG (for Your Favorite Gene). As haploid cells con-
tain one copy of each gene, recessive loss-of-function mutations
as well as dominant gain-of-function mutations can be obtained.
Examples include mutations in the drug target that render the
enzyme resistant to inhibition (such as the targets of rapamycin,
TOR1, and TOR2) (Heitman et al., 1991) or increased expres-
sion of a transcription factor that regulates the expression of a
drug-specific transporter (such as a dominant PDR1-10 mutant
which induces elevated the levels of the Snq2p transporter and
resistance to camptothecin) (Reid et al., 1997).
Similar strategies may be applied to mammalian cells in cul-
ture. However, the strength of the yeast system lies in the facile
genetics that enable the isolation and identification of the mutant
allele or dosage suppressor genes. Consider the resistant yfg
mutant isolated in Figure 1. The genetic manipulations dia-
grammed in Figure 2 will determine whether the mutant is reces-
sive or dominant and if the mutant phenotype derives from a sin-
gle gene mutation. This information will then determine how the
wild-type allele of yfg can best be isolated and characterized.
Identification of YFG (Your Favorite Gene)
Yeast cells exhibit highly regulated pathways of mating and
sporulation, which allow the recovery of all four meiotic spore
products encased in an ascus sac (Pringle and Hartwell, 1981;
Sherman, 2002). As shown in Figure 2, the haploid yfg mutant is
mated with an isogenic, unmutagenized YFG strain of opposite
mating type. The inclusion of different selectable markers in the
mutagen-treated MATa strain and the unmutagenized MATα
strain facilitates diploid strain selection (for instance, in a cross
of MATa, TRP1, his3∆, yfg cells with isogenic MATα, trp1∆,
HIS3, YFG cells, diploids are selected on media lacking trypto-
phan and histidine). The heterozygous yfg/YFG diploids can be
assessed for drug sensitivity to determine whether the drug-
resistant phenotype is recessive or dominant. As detailed
below, the recessive/dominant character of an yfg mutant will
dictate the means of identifying the ORF that was mutated.
In either case, an analysis of the meiotic products of sporu-
lation will determine whether the resistant phenotype is a con-
sequence of a single gene defect or if multiple mutations are
required. Obviously, the genetic analysis of single gene defects
is more straightforward. The sporulation program can be initiat-
ed by nutrient deprivation, and micromanipulation allows each
haploid spore to be isolated, germinated on rich media, and
examined for sensitive/resistant phenotypes (Sherman, 2002).
If drug resistance results from a single gene defect (or two
closely linked mutations), then wild-type and mutant alleles will
assort in approximately equal numbers to give a ratio of 2 resis-
tant:2 sensitive spore products per tetrad. If, on the other hand,
Figure 3. The isolation of mutants exhibiting conditional drug sensitivity
In this scheme, cells resistant to low concentrations of a drug are exposed
to a mutagen, and colonies exhibiting temperature-sensitive cell growth in
the presence of drug are isolated. The dashed lines indicate the lack of
colony formation at the restrictive temperature (35°C). This screen for drug-
induced synthetic lethality can also be exploited to define cold-sensitive
mutants.
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mutations in two unlinked genes are required for drug resis-
tance, then the random assortment of the wild-type and mutant
alleles will approach an overall ratio of 1 resistant:3 sensitive
spore products when multiple tetrads are examined.
Once single gene defects have been defined, successive
rounds of backcrossing mutant with wild-type cells followed by
selection of drug-resistant haploid spore products will eliminate
unrelated mutations that may affect cell growth. Since heavily
mutagenized cultures are typically used in genetic screens,
extensive backcrossing is critical for the subsequent characteri-
zation of yfg mutant phenotypes (Lawrence, 2002). If multiple
recessive yfg mutants are isolated, complementation analysis
(mating of each yfg mutant with another and assessing diploid
cell drug resistance) will determine whether the mutations are in
same gene or unlinked genes. For example, if diploid cells
obtained by mating recessive mutants yfg1 and yfg2 exhibit a
resistant phenotype, then the strains most likely harbor muta-
tion(s) in the same gene. If the yfg1, yfg2 diploid is sensitive to
the drug, then two genes are likely involved. This approach can
also be used to generate strains with the desired combination of
genetic mutations, selectable markers, and mating type for
additional studies.
For recessive yfg mutants, which segregate 2:2, the wild-
type YFG allele may be cloned by complementation of the resis-
tant phenotype (restoration of drug sensitivity). To achieve this,
haploid yfg cells are transformed with an YCp vector-based
yeast genomic library (Liu, 2002). Replica plating of the transfor-
mants onto selective media, plus or minus drug, will allow the
identification of yfg cells that harbor a plasmid-borne copy of the
wild-type YFG allele. Subsequent isolation of plasmid DNA from
single colonies grown in the absence of drug, followed by data-
base queries with sequences obtained from the yeast genomic
DNA insert, will define the YFG ORF. If the yfg mutant exhibits
other recessive phenotypes that reduce cell growth or viability
under different environmental conditions (such as an inability to
grow on a nonfermentable carbon source), the selection of the
wild-type YFG allele would simply involve screening for plasmids
that restore cell growth rather than inhibit colony formation.
To identify dominant YFG mutant alleles, a genomic YCp-
based DNA library is constructed with DNA isolated from the
mutant strain, which is then used to transform the recessive
wild-type cells to select for drug resistance (Reid et al., 1997).
Although this may seem an onerous undertaking, the construc-
tion of DNA libraries is quite straightforward (Liu, 2002), and the
efficiency of selecting drug-resistant colonies was established
in the initial screen. In either case, integrating a selectable
marker into the YFG locus in a wild-type haploid strain and
assessing the segregation of marker and drug resistance in
backcrosses with the yfg mutant will confirm the genetic identity
of the YFG clone.
If the YFG gene (or dosage suppressor gene) is nonessen-
tial, then targeted disruption of the chromosomal ORF will
determine if gene deletion exacerbates cell sensitivity to the
drug. If the gene product is well characterized, this approach
can provide an entrée into specific functional pathways.
Typically, more than one yfg mutant (or high copy suppressor)
will be obtained, which may comprise different components of a
given pathway or redundant functions. Alterations in cell mor-
phology and cell cycle distribution can also provide important
insights into drug action and suppressor functions.
Conditional mutants
Classic genetic screens, based on the acquisition of drug resis-
tance, are typically restricted to nonessential gene functions
and pathways affected by gene dosage. An alternative strategy
that avoids the lethal consequences of null mutations in essen-
tial genes is to screen for conditional mutants, where cell viabil-
ity is unaffected by drug action under one set of experimental
conditions and impaired under different conditions. As dia-
grammed in Figure 3, this approach can be adapted to select for
mutations in genes that normally protect cells from the adverse
affects of drug action (Fiorani and Bjornsti, 2000; Reid et al.,
1999). In the context of cancer therapeutics, the identification of
gene products or pathways that function to suppress the cyto-
toxic/cytostatic activity of a drug would provide important
insights into mechanisms regulating tumor cell response.
In this scenario, low concentrations of drug are insufficient
to inhibit wild-type yeast cell growth. Following mutagenesis,
viable cells are plated onto nonselective media at 25°C and
subsequently replica plated onto drug-containing media at 25°C
and 35°C. If the activity of a given gene product diminishes the
growth inhibitory effects of the drug (confers resistance), then
mutations that selectively impair gene function at 35°C would
exhibit drug-dependent cell death at the higher temperature
Figure 4. Synthetic lethal interactions
This figure compares the phenotypes of drug-induced synthetic lethality for
yfg1 and yfg2 strains at 35°C in the presence of drug and the synthetic
lethality induced by loss of redundant functions for the double yfg1, yfg2
mutant at 35°C in the absence of drug. Yellow plates lack drug, while blue
plates contain low concentrations of drug insufficient to inhibit wild-type
cell growth at any temperature. The dashed lines indicate the lack of
colony formation.
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(confer sensitivity). Rescreening for cell viability at 35°C in the
absence of drug will eliminate mutants exhibiting a temperature-
sensitive phenotype, independent of drug action. The spectrum
of temperature sensitive mutants isolated might include loss-of-
function mutations in nonessential genes, hypomorphic
(reduced activity) alleles of essential genes, gain-of-function
mutations, and dominant-negative mutations. A similar screen
for temperature-sensitive mutants exhibiting enhanced sensitiv-
ity to sublethal levels of a DNA topoisomerase I mutant enzyme
that mimics the cytotoxic action of camptothecin identified nine
gene products that function to suppress camptothecin-induced
cell death (Fiorani and Bjornsti, 2000; Reid et al., 1999). Six of
the nine genes (including CDC45, DPB11, and TAH11) are
essential. As mutant cell viability was not affected in the
absence of camptothecin-induced DNA lesions, sufficient gene
function was retained to maintain cell viability at 35°C.
Nevertheless, mutation-induced alterations in protein function
defined novel activities for these gene products in suppressing
the cytotoxic activity of camptothecin.
Conceptually, this approach is a modified synthetic lethal
screen (see below) where the combination of a nontoxic concen-
tration of drug with a nonlethal mutation induces cell death. This
suggests that a functional interaction between the gene product
and the drug (or drug-induced lesion) is required for cell viability.
Similar principles apply to redundant gene functions, where an
essential activity is provided by one of two gene products.
Synthetic lethality
As diagrammed in Figure 4, analyses of synthetic lethal interac-
tions constitute a powerful genetic strategy for defining function-
al interactions and defining pathways (Phizicky and Fields,
1995). Consider, for example, conditional yfg1 and yfg2 mutants
isolated in the screen for drug synthetic lethality at 35°C in
Figure 3. Based on the principles detailed in Figure 2, these sin-
gle gene defects involve different genetic loci, YFG1 and YFG2.
However, when the two mutant alleles are combined in a single
haploid cell, the double yfg1, yfg2 mutant cell exhibits a temper-
ature-sensitive phenotype in the absence of drug.This suggests
that both gene products function to suppress drug-induced
lethality, and that they also share a common essential function.
Indeed, a similar analysis of the cdc45-10 and dpb11-10
mutants isolated in the aforementioned screen for mutants
exhibiting enhanced sensitivity to topoisomerase I-targeted
drugs uncovered a synthetic lethal phenotype of the double
cdc45-10, dpb11-10 mutant at 35°C (Reid et al., 1999).The per-
sistent accumulation of Okazaki-sized DNA fragments in S
phase suggested a common essential function in processive
DNA replication that was also required for resistance to camp-
tothecin. The function of human homologs of CDC45 and
DBP11 in regulating tumor cell response to camptothecin is cur-
rently being pursued.
An analysis of mutant cell phenotypes, under restrictive
conditions, may also be informative and provides a means of
ordering gene function. For instance, if nonallelic mutations,
such as yfg1 and yfg2, induce distinct terminal phenotypes in
the presence of drug, then the phenotype of the double yfg1,
yfg2 mutant can be used to ascertain whether Yfg1p acts
upstream, downstream, or commensurate with Yfg2p.
Genetic interactions
Alterations in yfg1 mutant phenotype can be exploited in sec-
ondary genetic screens to (1) isolate dosage suppressors of
drug-induced yfg1 cell death or (2) screen for compensatory
mutations in genes other than yfg1 that restore cellular resis-
tance after EMS mutagenesis. Potential mechanisms include
the stabilization of a thermolabile Yfg1 protein, an increase in
compensatory or redundant repair pathways, increased expres-
sion of a transporter, or a compensatory change in protein
structure that restores protein-protein interactions.
Ultimately, biochemical studies of alterations in protein
function and protein-protein interactions predicted by such
genetic interactions will provide a more compelling insight into
drug mechanism. Nevertheless, with the principles laid out in
this primer, it is possible to define the cellular target of an
unknown agent and to genetically decipher the functional com-
ponents of a pathway or pathways that regulate cellular
responses to a given drug. These findings may have immediate
impact in the clinical development of novel therapeutics or sug-
gest novel targets for future drug development.
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